drugset / Trial / NCT02422966

Paracetamol in Patent Ductus Arteriosus

NCT02422966

Phase 2 Completed 110 enrolled Angelini Pharma
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to assess the efficacy and safety of paracetamol in comparison to ibuprofen in the treatment of patent ductus arteriosus (PDA) in preterm infants.

Timeline

Start
2015-12
Primary completion
2019-01
Completion
2019-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Acetaminophen Small molecule 15 mg/kg Intravenous
Comparator Ibuprofen Small molecule 5 mg/kg Intravenous